SYK and neoplasm: Reduction of oral xenograft tumor volume with paralleling decrease in Syk and PLK1 expression, as well as chemosensitization of platinum drug in vivo, together with overexpression of Syk and PLK1 in clinical OSCCs provided evidence for development of ER maleate as a novel therapeutic agent for OSCC.